U.S. Consumer Services Stock News

NasdaqGS:IONS
NasdaqGS:IONSBiotechs

Ionis (IONS) Wins Tryngolza Approval And Recordati Deal For Zilganersen

Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA approval for Tryngolza (olezarsen) as the first treatment to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia. The company plans a U.S. commercial launch of Tryngolza next month, targeting high risk patients with limited existing options. Ionis also signed a licensing agreement granting Recordati exclusive rights to develop and commercialize zilganersen for Alexander disease outside the U.S.,...
NYSE:CVSA
NYSE:CVSAConsumer Services

Can Truist’s Chamberlain Enrollment Optimism Reshape Covista’s (CVSA) Healthcare Education Earnings Mix?

Recently, analyst commentary from Truist pointed to a credible path for Covista’s Chamberlain University to return to mid-to-high single-digit enrollment growth, reinforcing management’s focus on expanding this healthcare education segment. The emphasis on Chamberlain’s potential enrollment recovery highlights how improving student intake at a single, core institution could meaningfully influence Covista’s overall education portfolio and earnings mix. We’ll now examine how this renewed...
NasdaqGS:ROST
NasdaqGS:ROSTSpecialty Retail

Ross Stores (ROST) Is Still Winning Inflation Weary Shoppers In Store

Ross Stores (NasdaqGS:ROST) is drawing inflation weary shoppers across income brackets with its value focused, off price model. The company is seeing sustained interest in its brick and mortar stores even as many retailers emphasize digital channels. This contrast highlights Ross Stores' differentiated approach at a time when in person discount shopping continues to appeal to budget conscious consumers. Ross Stores runs an off price retail model built around in store treasure hunt style...
NasdaqGM:CRSP
NasdaqGM:CRSPBiotechs

What CRISPR Therapeutics (CRSP)'s Upgraded Revenue and EPS Forecasts Mean For Shareholders

In recent days, analysts raised their consensus revenue forecasts for CRISPR Therapeutics and projected year-over-year EPS growth ahead of the company’s upcoming earnings report. This shift in expectations has drawn attention to how confidence around near-term gene-editing revenue potential may be reshaping perceptions of CRISPR Therapeutics’ business outlook. We’ll now examine how heightened analyst optimism about CRISPR Therapeutics’ near-term revenues could influence the company’s...
NasdaqGS:ALHC
NasdaqGS:ALHCHealthcare

Healthcare Stocks Investors Are Watching For Stability As The Jobs Market Softens

With markets watching a softer May jobs report, muted hiring, elevated layoffs, and a Federal Reserve that may be reluctant to shift rates quickly, many investors are taking a fresh look at stocks that could hold up when growth feels less certain. This article focuses on three stocks from a Defensive Sectors screener, all from Utilities, Consumer Staples, and Healthcare, that are directly exposed to the latest labor market news. Each has been selected for financial strength within its sector,...
NasdaqGS:GLXY
NasdaqGS:GLXYCapital Markets

Galaxy Digital (NasdaqGS:GLXY) And The Tokenization Story Behind Its Fair Value Gap

Recent Share Performance and Business Mix Galaxy Digital (GLXY) has seen mixed share performance recently, with the stock up 3.5% over the past day but down 14.4% over the past week and about 1.1% over the past month. Over the past 3 months, Galaxy Digital is up about 70.6%, with a total return of 46.5% over the past year and a very large gain across the past 3 years. Year to date, the stock is up 18.2%. The company reports annual revenue of US$58,713.02, primarily from its Digital Assets...
NYSE:CNR
NYSE:CNROil and Gas

What Core Natural Resources (CNR)'s Leer South Restart and New Coal Contracts Mean For Shareholders

Core Natural Resources recently restarted longwall mining at its Leer South mine and secured major contracts across its segments at favorable prices, reinforcing operational momentum despite broader coal industry headwinds. This combination of restored production capacity and contracted volume visibility could meaningfully influence how investors assess the resilience and cash generation profile of the business. We’ll now examine how the Leer South longwall restart and newly secured...
NasdaqGM:USAR
NasdaqGM:USARMetals and Mining

USA Rare Earth (USAR) Plans Brazilian Mine Deal To Lock In Non Asian Feedstock

USA Rare Earth (NasdaqGM:USAR) plans to acquire a producing mine in Brazil, with completion targeted for 2026. The company intends to integrate the mine's output into its global value chain to secure non Asian rare earth feedstock. This development is separate from the recent Wheat Ridge facility commissioning and focuses on expanding upstream supply. USA Rare Earth is drawing fresh attention as it moves to add a producing Brazilian mine to its portfolio, reinforcing its role in rare earth...
NasdaqGS:CPB
NasdaqGS:CPBFood

Is Campbell's (CPB) Gluten Free Pivot Quietly Redefining Its Core Brand and Investor Story?

In June 2026, Campbell’s and Banza launched a new gluten free condensed Chicken Noodle Soup made with chickpea penne pasta, while Campbell’s also announced upcoming retirements and internal promotions in its transformation and communications leadership, and the stock was added to the Russell Small Cap Comp Value Index. This combination of a milestone gluten free product aimed at health-conscious consumers, leadership transitions, and fresh index inclusion highlights how Campbell’s is...
NasdaqGS:LAUR
NasdaqGS:LAURConsumer Services

Laureate Education (LAUR) Could Be 54% Undervalued On Weak Enrollment And Cash Flow Concerns

Recent commentary on Laureate Education (LAUR) centers on weak student enrollment growth, flat earnings per share and disappointing free cash flow projections, which raise questions about demand, operational efficiency and the downside risks already reflected in the stock price. See our latest analysis for Laureate Education. At a share price of $37.12, Laureate Education has a 1 month share price return of 16.04% and a 1 year total shareholder return of 60.69%. This puts recent momentum...
NYSE:AMPY
NYSE:AMPYOil and Gas

Cheniere Energy Stock And 2 US Energy Names Tied To Gulf Export Demand

Fresh headlines around potential changes to US sanctions on Venezuela have put US oil refiners back in focus, as traders weigh what cheaper heavy crude access could mean for costs, margins, and long term capital plans. This article looks at how that news ties into a curated screener of larger, financially healthier US refining companies, and why the shift in Venezuelan exports away from China toward the US matters for anyone watching energy stocks. Below, you will see 3 stocks from this...
NasdaqGS:TXG
NasdaqGS:TXGLife Sciences

10x Genomics (TXG) Is Up 5.7% After Cleveland Clinic Precision-Oncology Biomarker Collaboration News - What's Changed

In June 2026, Cleveland Clinic announced a multi-year research collaboration with 10x Genomics to use its Flex Apex, Xenium and future Atera platforms to analyze advanced bladder cancer tumor samples and uncover treatment-response biomarkers for potential diagnostic development. This partnership aims to generate a rich, multimodal dataset that links single-cell and spatial profiles with clinical outcomes, potentially reinforcing 10x Genomics’ role in precision oncology research and future...
NYSE:ASAN
NYSE:ASANSoftware

Asana (ASAN) Wins FedRAMP Approval, Is The Stock Still Undervalued?

Asana (ASAN) is in focus after announcing that its Asana Gov platform has achieved FedRAMP Moderate Authorization. This opens the door to public sector clients that require specific federal security and compliance standards. See our latest analysis for Asana. The FedRAMP news arrives as Asana’s 1 day share price return of 9.08% and 90 day share price return of 12.97% contrast with a sharply weaker year to date share price return of 46.22% and 1 year total shareholder return decline of 47.52%...
NasdaqGS:UFCS
NasdaqGS:UFCSInsurance

Why United Fire Group (UFCS) Is Up 8.8% After Earnings Beat And Top Analyst Ranking - And What's Next

In recent months, United Fire Group reported earnings that exceeded expectations and earned a top analyst ranking, highlighting resilient operations and disciplined execution. This combination of positive earnings surprise and attractive value metrics has drawn fresh investor attention to a business already focused on underwriting discipline and expense control. We’ll now examine how this earnings beat and value appeal may influence United Fire Group’s existing investment narrative and...
NasdaqGS:WDFC
NasdaqGS:WDFCHousehold Products

WD-40 (WDFC) Wins A Buy Call, Is The Stock Fully Valued?

WD-40 (WDFC) drew fresh attention after Northcoast Research began coverage with a positive rating, coinciding with strong profitability metrics such as a 54.9% gross margin and a 26.1% return on invested capital. See our latest analysis for WD-40. WD-40’s recent momentum has been strong, with a 20.82% 1 month share price return and a 26.21% year to date share price return, while the 3 year total shareholder return sits at 38.26%, indicating that recent optimism is building on a longer record...
NYSE:CVNA
NYSE:CVNASpecialty Retail

Carvana (CVNA) Expands Sarasota Capacity, Is The Stock Still 32% Undervalued?

Carvana (CVNA) has moved to expand its operations by adding Inspection and Reconditioning Center capabilities to its ADESA Sarasota auction site, creating more reconditioning capacity and a new local inventory pool. See our latest analysis for Carvana. Carvana's expansion in Sarasota comes at a time when the stock has been under pressure in the short term, with the share price down 14.59% over the past 30 days and 22.11% year to date, even as the 3 year total shareholder return exceeds 10x...
NasdaqGS:PRAX
NasdaqGS:PRAXBiotechs

Praxis Precision Medicines (PRAX) Is Up 16.1% After FDA Grants Breakthrough Tag To Elsunersen

Earlier this week, Praxis Precision Medicines announced that the FDA granted Breakthrough Therapy Designation to elsunersen (PRAX-222) for treating seizures in children with SCN2A developmental and epileptic encephalopathy caused by gain-of-function SCN2A variants, based on positive EMBRAVE Part A trial data. The designation, layered on top of multiple US and European rare disease incentives, underscores elsunersen’s potential to address a severe epilepsy with no approved genetically...
NYSE:PRA
NYSE:PRAInsurance

ProAssurance (PRA) Trades At A Premium, Is The Upside Already Priced In?

Recent Performance Snapshot for ProAssurance Stock ProAssurance (PRA) has drawn investor attention after recent trading, with the stock last closing at $25. Over the past month, the share price return was 4.6%, and about 1.7% over the past 3 months. See our latest analysis for ProAssurance. Looking beyond the past quarter, ProAssurance’s 1-year total shareholder return of 9.5% contrasts with more moderate recent share price gains. This may hint that earlier momentum has cooled and that...
NYSE:KEYS
NYSE:KEYSElectronic

Can Keysight Technologies (KEYS) Justify Its Valuation After Strong Earnings And Raised Guidance?

Keysight Technologies (KEYS) is back in focus after its latest quarterly report topped earnings forecasts, with order growth above 30% year on year and management raising revenue expectations for the period. See our latest analysis for Keysight Technologies. Despite the upbeat earnings news, Keysight Technologies’ recent 1-day and 7-day share price returns are both down around 9%, even though the 90-day share price return is up 17.77% and the 1-year total shareholder return is close to 100%...
NYSE:USNA
NYSE:USNAPersonal Products

3 Consumer Staples Stocks For Investors Watching Household Budget Pressure

With long term unemployment rising in the U.S. and more households under pressure, investors are paying closer attention to how reduced spending might feed through to company revenues and profits. Essential consumer goods stocks can sometimes hold up differently when budgets tighten, but the impact is not uniform. This article looks at how this labor market shock connects to larger food, beverage, and personal care companies, and what that might mean for their risk and resilience. Ahead, you...
NasdaqGS:WSBC
NasdaqGS:WSBCBanks

Is WesBanco (WSBC) A Bargain After Its Recent Share Price Rally?

WesBanco (WSBC) is drawing attention after recent share price gains, with the stock last closing at $38.80. For investors, the key question is how this performance aligns with the bank’s underlying fundamentals. See our latest analysis for WesBanco. Recent trading suggests momentum is building, with WesBanco’s 1 month share price return of 12.14% and 16.38% year to date, set against a 1 year total shareholder return of 28.13% and 3 year total shareholder return of 74.77%. If you are looking...
NasdaqGS:PAYX
NasdaqGS:PAYXProfessional Services

Does Slower 2027 Guidance After Strong 2026 Results Change The Bull Case For Paychex (PAYX)?

In June 2026, Paychex reported full-year 2026 results showing revenue of US$6.51 billion and net income of US$1.76 billion, alongside completing a US$686 million share repurchase program covering 1.79% of shares. Despite double-digit growth in the recent quarter and new AI and Paycor contributions, management’s 5–6% revenue growth guidance for fiscal 2027 points to a more measured expansion phase. Next, we’ll examine how Paychex’s strong 2026 results but slower 2027 revenue guidance affect...
NYSE:MSM
NYSE:MSMTrade Distributors

Does Higher Dividend And Brighter Earnings Outlook Change The Bull Case For MSC Industrial Direct (MSM)?

MSC Industrial Direct Co., Inc. recently declared a quarterly dividend of US$0.87 per share, payable on July 22, 2026, to shareholders of record as of the July 8 ex-dividend date. At the same time, analysts have become more optimistic about MSC Industrial Direct’s upcoming May-quarter earnings, with the Most Accurate Estimate now above the wider consensus. Next, we’ll examine how this higher dividend and improving earnings sentiment might influence MSC Industrial Direct’s existing investment...
NasdaqGS:BCRX
NasdaqGS:BCRXBiotechs

BioCryst Pharmaceuticals (BCRX) Reports Strong Orladeyo Data, Is The Upside Already Priced In?

Recent Orladeyo Data and Revenue Outlook Put BioCryst Pharmaceuticals (BCRX) in Focus Fresh efficacy data for BioCryst Pharmaceuticals (BCRX) lead therapy Orladeyo in young hereditary angioedema patients, alongside full-year revenue guidance of US$625 million to US$645 million, has put the stock in the spotlight. See our latest analysis for BioCryst Pharmaceuticals. The recent Orladeyo data and revenue outlook appear to sit alongside firm price momentum for BioCryst Pharmaceuticals, with a 7...